Earnings Call Summary | Renalytix(RNLX.US) Q3 2024 Earnings Conference
Earnings Call Summary | Renalytix(RNLX.US) Q3 2024 Earnings Conference
The following is a summary of the Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript:
以下是Renalytix Plc（RNLX）2024年第三季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Renalytix reported revenue of $535,000 for Q3 2024, a decrease from the previous year due to changes from the original contract model with Mount Sinai.
Operating expenses were reduced by 40% to $6.5 million, including a 50% reduction in headcount and vendor reductions.
Net loss improved by 36% to $7.7 million compared to the same quarter the previous year.
The company had a cash amount of approximately $4.7 million at the end of the quarter.
Renalytix reported 806 total tests for the quarter, 82% of which were billable.
Renalytix報告稱，2024年第三季度收入爲53.5萬美元，比上年有所下降，這是由於與西奈山的原始合同模式發生了變化。
運營費用減少了40％，至650萬美元，其中包括裁員50％和裁減供應商。
與去年同期相比，淨虧損增長了36％，達到770萬美元。
截至本季度末，該公司的現金額約爲470萬美元。
Renalytix報告了本季度共進行了806次測試，其中82％是計費的。
Business Progress:
業務進展：
Renalytix received a draft local coverage determination (LCD) for KidneyIntelX from the Medicare contractor and expects a final decision soon.
KidneyIntelX was included in the final international clinical guidelines for chronic kidney disease.
The company launched the FDA-approved KidneyIntelX product and started receiving commercial test orders.
The company managed to reduce overall operational expenses by about 60%, showing efficiency in cost management.
Renalytix initiated the formal sales process after showing promising interest from a diagnostics company.
KidneyIntelX has shown significant clinical improvement in patient health including decreased kidney damage and improvement in blood pressure.
The company identified five key markets showing maximum potential and is planning to increase the sales force to capture more opportunities.
Renalytix is aiming for broad adoption of its KidneyIntelX test by highlighting the cost benefits and patient outcomes to insurance companies.
Renalytix收到了醫療保險承包商的KidneyIntelX當地保險決定草案（LCD），預計不久將做出最終決定。
KidneyIntelX被納入慢性腎臟病的最終國際臨床指南。
該公司推出了經美國食品藥品管理局批准的KidneyIntelX產品，並開始接收商業測試訂單。
該公司設法將總運營支出減少了約60％，顯示了成本管理的效率。
Renalytix在一家診斷公司表現出濃厚的興趣後，啓動了正式的銷售流程。
KidneyIntelX 在患者健康方面顯示出顯著的臨床改善，包括腎臟損傷減少和血壓改善。
該公司確定了五個顯示最大潛力的關鍵市場，並計劃增加銷售隊伍以抓住更多機會。
Renalytix的目標是通過向保險公司強調成本效益和患者預後，廣泛採用其KidneyIntelX測試。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。